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Abstract
Purpose—African American men have the highest incidence of prostate cancer among ethnic 
groups, and racial disparity is highest in younger men. Prostate cancer prevalence is rising in HIV-
infected men due to improved survival on antiretroviral therapies, yet little is known about racial 
differences in prostate cancer risk by HIV-infection status and age.
Methods—Prospective cohort study of prostate cancer risk in 2800 HIV-infected and -uninfected 
men who have sex with men (MSM) ages 40–70 (22% African American) in the Multicenter 
AIDS Cohort Study from 1996–2010. Poisson regression models were used to examine 
associations between race or HIV-infection status and prostate cancer risk among men ages 40–70, 
40–55, and 56–70.
Results—Among men ages 40–70, incidence rates (IR) per 100,000 person years were 169 
among all men and 276 among African American HIV-infected men. Prostate cancer risk was 
similar by HIV-infection status (IRR 1.0, 95% CI 0.55–1.82), but nearly 3-fold higher in African 
Americans compared to non-African Americans in adjusted models (IRRs 2.66 and 3.22, 95% CIs 
1.36–5.18 and 1.27–8.16 for all or HIV-infected men, respectively). Racial disparity in prostate 
cancer risk was greatest in African American men ages 40–55 (adjusted IRR 3.31, 95% CI 1.19–
9.22). Prostate cancer risk showed associations with family history of prostate cancer (p =0.001), 
but not heavy smoking, androgen supplement use, or HIV-related factors.
Conclusions—Among MSM, African American HIV-positive and HIV-negative men ages 40–
55 have nearly a 3-fold increased risk of young-onset prostate cancer compared to non-African 
American men, highlighting the need to make informed decisions about screening in this 
population.
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Prostate cancer is the most common non-cutaneous cancer among men (1), and incidence 
rates have been rising over time among HIV-infected men due to improved survival on 
newer antiretroviral therapies (ART) (2). Prostate cancer presents some unique challenges in 
HIV-infected populations, including higher cancer-specific mortality rates in comparison to 
HIV-uninfected populations (3) and lower rates of prostate-specific antigen (PSA) screening 
in subpopulations, including racial and sexual minorities (4–6). Major established risk 
factors in the general population are older age, African American race, and family history of 
prostate cancer (7, 8); modifiable risk factors include androgen supplement use and obesity 
(9, 10). The influence of HIV-related factors on prostate cancer risk remains poorly defined 
(11).
Previous studies report contradictory findings regarding the incidence rates of prostate 
cancer in HIV-infected compared to uninfected men. Several studies have reported lower 
incidence rates of prostate cancer among men with HIV infection and/or AIDS compared to 
the general population (9, 12–14). Proposed explanations for the lower prostate cancer 
incidence rates in HIV-infected men in these studies include lower PSA screening rates, 
competing risks from HIV-related comorbidities and mortality, and androgen deficiency, 
which is common in HIV-infected populations (12). However, other studies found similar or 
slightly higher incidence rates of prostate cancer in HIV-infected compared to uninfected 
men (15–18). Given these contradictory results, the effect of HIV infection on prostate 
cancer risk remains unclear in the highly active antiretroviral therapy (HAART) era.
Several studies have reported trends toward a younger age at prostate cancer diagnosis in 
HIV-infected compared to uninfected men (5, 19, 20). A recent study in the largest HIV 
cohort in North America found that while age at prostate cancer diagnosis was younger 
among HIV-infected subjects, the difference was not statistically significant (21); findings 
were inconclusive with respect to young-onset prostate cancer in groups by HIV status 
because age was examined in 10-year bins rather than comparing age of young-onset 
prostate cancer cases by HIV status. Young-onset prostate cancers diagnosed before age 55 
are biologically and genetically distinct compared to prostate cancers diagnosed in older 
men (8, 22). Moreover, high-grade prostate cancers occurring before age 55 have a higher 
risk of cancer-specific mortality (23). PSA screenings have greatly improved early detection 
of prostate cancers (7, 24), and detection rates of young-onset prostate cancer have increased 
from 2.3% of total prostate cancers diagnosed in the early-PSA era (1988 to early 1990s) to 
9–10% in the post-PSA era (8, 25). American Cancer Society (ACS) guidelines suggest 
screening at age 40 for men with multiple first-degree relatives with prostate cancer, age 45 
for African Americans and men with a single first-degree relative diagnosed with prostate 
cancer at age < 65, and age 50 for men at average risk. With exception of a study by Riedel 
et al. (5), little is known about young-onset prostate cancer among HIV-infected men in the 
HAART era. Given the evolving epidemiology of prostate cancer risk in HIV-infected men 
on newer ART regimens, further study is needed to understand if subpopulations of people 
living with HIV or AIDS (PLWHA) may be at heightened risk at an earlier age.
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African American men have a higher risk of prostate cancer in comparison to non-African 
men, including a higher incidence of young-onset prostate cancer (26). African American 
men are also at higher risk for more aggressive tumors, and higher prostate cancer-related 
mortality. Management of prostate cancer risk and outcomes in African American men is 
influenced by racial disparities in health care access, surveillance, treatment, and survival (5, 
6, 8, 26, 27). African American men are disproportionately represented among HIV-infected 
men, a population more vulnerable to health care disparities in comparison to uninfected 
men (5, 27, 28). A recent study in the HAART era found that HIV-infected men were largely 
appropriately treated in comparison to HIV-uninfected men, though under- or over-treatment 
sometimes occurred due to difficulty estimating life expectancy (27); disparities by HIV 
status remained for some treatment options such as radical prostatectomy, which was 
performed less frequently in those with HIV-infection. Although prostate cancer is becoming 
more prevalent among HIV-infected men in the HAART era, the effect of race on prostate 
cancer incidence in HIV-infected populations remains unknown. Considering these 
disparities by race and HIV-infection status, together with evidence of increased prostate 
cancer mortality (3) and lower rates of PSA screening in some HIV-infected cohorts (12), a 
better understanding of prostate cancer risk in HIV-infected men is needed to optimize 
cancer surveillance and health outcomes overall, and among sexual and racial minority 
groups. A retrospective study of prostate cancer outcomes in a predominantly African 
American HIV-infected urban cohort cited a high prevalence of intravenous drug use (IDU) 
and hepatitis C virus (HCV) infection in the study cohort as confounding factors, since these 
factors often influence linkage to care, comorbidities, and survival (5). Prospective cohort 
studies controlling for these and other confounding factors will provide more accurate 
estimates of prostate cancer risk by age and race in HIV-infected men.
The Multicenter AIDS Cohort Study (MACS), an observational cohort study based in four 
urban areas in the United States, offers important advantages because HIV-infected and 
uninfected populations are similar for demographics and lifestyle, which serves as an 
internal control. Here, we investigate the association between African American race, HIV-
infection status, and prostate cancer risk in HIV-infected and uninfected men who have sex 
with men using longitudinal data from the MACS.
Methods
Study cohort
This is a nested prospective study in the MACS, an ongoing cohort study of men who report 
sex with men (MSM). Established in 1984, the MACS has enrolled 6972 HIV-infected and 
HIV-uninfected MSM over 3 recruitment waves (1984–85 (n=4957), 1987–91 (n=665), 
2001–03 (n=1350)) at 4 study sites (Los Angeles, Chicago, Baltimore, and Pittsburgh) as 
described in (29), with a focus on recruitment of racial and ethnic minorities during the third 
wave. Behavioral, clinical, and laboratory data were collected at semi-annual visits as 
described (30). Eligible participants were 2800 HIV-infected and HIV-uninfected men over 
age 40 with least one study visit between 1996–2010 and no prior prostate cancer diagnosis 
at the beginning of follow-up (recruitment waves 1984–85 (n= 1766), 1987–91 (n= 212), 
2001–03 (n= 822)). Follow-up began in 1996 at the earliest visit between ages 40–70. 
Dutta et al. Page 3













Institutional Review Boards at each study site approved the research and written informed 
consent was obtained from all individual participants included in the study.
Data collection and covariates
The MACS public dataset (P23 release) was translated into a local SQL database and used 
for the analyses. HIV-infection status was coded as a time-invariant covariate based on 
seroconversion before study entry. Early HAART (1996–2000) vs. late HAART (2001–
2010) era was treated as a time-varying covariate. HBV and HCV infection status, heavy 
smoking, and BMI values were summarized using data nearest to end of follow-up. Subjects 
were classified as intravenous drug users (IDU) if injection drug use was self-reported for at 
least year during follow-up. The follow-up period for each subject was defined as the first 
visit after age 40 in 1996 or later until first instance of incident prostate cancer, loss to 
follow-up, or last visit in 2010. Androgen supplement use and family history of prostate 
cancer were evaluated between enrollment and end of follow-up. HIV-related variables such 
as ART use, protease inhibitor (PI) use, plasma viral load, CD4 cell count, CD4:CD8 ratio, 
and AIDS diagnosis were summarized using data nearest to end of follow-up in HIV-positive 
subjects.
Cancer outcomes
A total of 47 incident prostate adenocarcinomas diagnosed during the study period were 
identified using International Classification of Diseases for Oncology, third edition (ICD-
O-3) codes. Incident cancers were ascertained continuously during follow-up using cancer 
registry linkage data, available medical records and death certificates, and self-reported 
cancer diagnoses (30).
Statistical Analysis
Incidence rates (IR) per 100,000 person-years were calculated by dividing the total number 
of incident cancers by cumulative years of follow-up. Follow-up was defined by last visit, 
death, or first instance of the incident cancer. Poisson regression models adjusted for age (> 
age 55 vs. <=55 years), race (African American vs. non-African American), HIV-infection 
status, and calendar period (early vs. late HAART era) were used to examine risk of prostate 
cancer; incidence rate ratios (IRR) and 95% confidence intervals (CI) were estimated. 
Subgroup analyses by age (<= age 55 and >55 years) were conducted. Post-hoc analysis 
examined clinical characteristics in age-stratified groups by prostate cancer diagnosis. 
Statistical analysis was performed using the ‘stats’ package of R version 3.2.1.
Results
We identified a cohort of 2800 men between ages 40–70 enrolled in the MACS from 
between 1996–2010, contributing 24,016 person-years (n=1448 HIV-uninfected and n=1352 
HIV-infected men with median follow-up of 14 and 8 person-years, respectively) (Table 1). 
Comparing prostate cancer risk factors in groups by HIV status, HIV-infected compared to 
uninfected subjects were younger at baseline, median age (IQR), 42 (40–47) vs. 45 (40–50) 
years, respectively, and had a lower proportion with BMI>30 kg/m2 and higher proportion of 
African Americans, heavy smokers, and exogenous androgen supplement use (testosterone, 
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dehydroepiandosterone (DHEA), Oxandrolone, or Nandralone) during follow-up compared 
to uninfected subjects (27.9% compared to 1.1%, respectively). Additionally, a higher 
proportion of HIV-infected subjects were HBV- or HCV-infected. Among HIV-infected 
subjects at follow-up, mean CD4 cell count was 516 cells/μl, 90.2 % reported ART use, and 
29.4% had plasma viral load > 400 RNA copies/ml (at or above the limit of detection of the 
available test at some earlier visits); 40.6% had CD4 nadir <200 cells/ μl and 27.5 % had an 
AIDS diagnosis before study endpoint (Table 1). In groups by race, African Americans were 
significantly younger at baseline and had shorter follow-up in comparison to non-African 
Americans; median (IQR) age and duration within study for African Americans vs. non-
African Americans was 42 (40–46) vs. 44 (40–49) years and 7 (7–8) vs. 14 (7–14) years. In 
comparison to non-African Americans, a lower proportion of African Americans were heavy 
smokers and reported androgen supplement use, while a higher propotion had BMI>30 
kg/m2 and HIV- or HCV-infection. HIV-infected African American subjects reported less 
ART use (84.3% vs. 92.4%), had a higher proportion with unsuppressed viral load > 400 
copies/ml (35% vs. 24.1%), and lower proportion with an AIDS diagnosis before study 
endpoint (16.9% vs. 31.4%) in comparison to HIV-infected non-African Americans. The 
proportion of subjects reporting a positive family history of prostate cancer was similar 
between groups by HIV-infection status and race.
A total of 47 incident prostate cancer diagnoses were identified among the participants: 45 
with prostate cancer as the first cancer diagnosis, and 2 with Kaposi sarcoma or Non-
Hodgkin lymphoma diagnoses preceding the prostate cancer diagnosis. The crude IRs of 
prostate cancer among all, HIV-positive, and HIV-negative subjects were 169, 185, and 150 
per 100,000 person-years, respectively (Table 2). Prostate cancer had nearly two-fold higher 
crude IRs among African-American compared to non-African American subjects ages 40–
70 (267 and 148 per 100,000 person-years, respectively). Among groups by race and HIV 
status, HIV-infected African Americans had the highest crude IR relative to other groups 
(crude IR 276 per 100,000 person-years). Among subjects age 40–55, crude IRs were more 
than 3-fold higher in African Americans compared to non-African Americans (crude IR 200 
vs. 60 per 100,000 person-years, respectively).
In Poisson regression models adjusted for age, race, and HAART era, there was no 
significant association between HIV-infection status and prostate cancer risk among subjects 
age 40–70 (IRR 1.0, 95% CI 0.55–1.82) (Table 3). By contrast, prostate cancer incidence 
rates were significantly higher among African American compared to non-African American 
subjects age 40–70 in adjusted models for all subjects (IRR 2.66, 95% CI 1.36–5.18) or only 
HIV-infected subjects (IRR 3.22, 95% CI 1.27–8.16). As expected, the incidence rate was 
significantly higher in subjects > age 55 compared to age < =55 in adjusted models for all 
subjects (IRR 6.08, 95% CI 3.24–11.41) or only HIV-infected subjects (IRR 6.98, 95% CI 
2.74–17.78).
Sixteen subjects met criteria for young-onset prostate cancer, with diagnoses by age 55; the 
age ranges at time of young-onset prostate cancer diagnosis were 41–50 years in HIV-
positive compared to 50–54 years in HIV-negative subjects, a difference that was not 
statistically significant (p=0.11). To investigate risk of young- and older-onset prostate 
cancer in African American compared to non-African American subjects, we evaluated 
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Poisson regression models stratified by age (Table 3). When stratifying by age, prostate 
cancer incidence rates were similar in HIV-infected vs. uninfected subjects ages 40–55 and 
56–70 in adjusted analyses (IRRs 0.89 and 1.07; 95% CIs 0.33–2.41 and 0.51–2.26, 
respectively). By contrast, African American subjects had a significantly increased risk of 
young-onset prostate cancer in adjusted analyses (IRR 3.31, 95% CI 1.19–9.22); the risk of 
older-onset prostate cancer was also elevated (IRR 2.29, 95% CI 0.92–5.67).
Next, we compared clinical characteristics by presence or absence of a prostate cancer 
diagnosis for subjects ages 40–70 and younger (ages 40–55) and older (ages 56–70) age 
strata (Table 4). Among men ages 40–70, subjects with a prostate cancer diagnosis were 
significantly older than non-outcome subjects at age of diagnosis or end of follow-up 
(median age 58 vs. 53 years; p=.004) and a higher proportion had a positive family history 
of prostate cancer in comparison to non-outcome subjects (25.5% vs. 12.1%, p=0.001); other 
variables showed no significant difference. Among men age 40–55, subjects with a prostate 
cancer diagnosis had a greater proportion of African Americans (43.7% vs. 22.8%; p=0.047) 
or family history of prostate cancer (18.8% vs. 12.3%; p=0.43). HIV-related covariates, 
including CD4 cell count s, HIV viral load s, ART use, and PI use, were generally balanced 
between groups by prostate cancer diagnosis, excepting a lower proportion with AIDS 
diagnoses among outcome versus non-outcome subjects ages 40–70 (10.5% vs. 27.8%; 
p=0.066) and ages 56–70 (0% vs. 28.7%; p=.053), which most likely explains the difference 
in CD4:CD8 ratios between groups. Androgen supplementation, which is common among 
young gay and bisexual men (31), was not higher in younger compared to older HIV-positive 
subjects (22.4% vs. 40.6%, respectively). Similarly, androgen supplementation was not 
higher in younger vs. older HIV-infected African Americans (9.6% vs. 19.5%). Furthermore, 
no prostate cancer cases among African Americans reported androgen supplement use. 
Three subjects with prostate cancer diagnoses died while being followed in the MACS, one 
due to prostate cancer-related causes and two from causes unrelated to prostate cancer.
Discussion
In this prospective cohort study of HIV-infected and uninfected men who have sex with men 
ages 40–70, African American race was associated with a 2.7-fold increase in prostate 
cancer risk overall. African American race was associated with more than 3-fold increase in 
prostate cancer risk among younger men ages 40–55. This is the first unbiased measure of 
young-onset prostate cancer risk by race among HIV-infected and uninfected men, 
irrespective of a positive family history of prostate cancer. As expected, increasing age was 
significantly associated with elevated prostate cancer risk overall and in models restricted to 
HIV-infected men. While a null association was observed between HIV-infection and 
prostate cancer risk in groups by age, a suggestion of increasing prostate cancer incidence 
among HIV-infected men ages 40–70 in the late HAART era was supported by a trend 
toward a negative association between early HAART era and prostate cancer risk.
Prostate cancer incidence rates by race and HIV-infection status were highest among HIV-
infected African American men relative to other groups (crude IR 276 per 100,000 person-
years). The racial differences in prostate cancer risk we detected are largely consistent with 
findings in the general population (9); in our cohort, the greatest racial disparity in incidence 
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rate was in younger men ages 40–55. The association of African American race with nearly 
a 3-fold higher risk of prostate cancer in HIV-infected and uninfected men ages 40 to 70 was 
not attenuated in adjusted models restricted to subjects ages 40–55. As the HIV-infected 
population grows in the HAART era, identifying high-risk groups and optimizing their 
linkage to care will help to reduce disparities in prostate cancer diagnosis, treatment, and 
survival. The trend of increased risk of prostate cancer diagnosis among young HIV-infected 
and uninfected men in our cohort is also consistent with studies reporting a 1.5- to 3-fold 
increased risk of young-onset prostate cancer in African Americans compared to Caucasians 
in the general population (8, 25, 26).
Several studies reported a deficit in risk of prostate cancer among HIV-infected men (9, 12–
14). However, we found similar risk of prostate cancer in HIV-infected compared to 
uninfected men who have sex with men, ages 40–70, 40–55, and 56–70. Our finding that 
prostate cancer incidence rates are similar by HIV-infection status is consistent with other 
studies (15), (18) and earlier study in the MACS (30). Differences in prostate cancer 
incidence rates reported here compared to studies reporting a deficit of prostate cancer risk 
in HIV-infected populations may be explained by several factors (9, 12–14). The lower 
prevalence of AIDS and AIDS-related deaths in our study and reported by Seaberg et al. (30) 
compared to some earlier studies (9, 12, 13, 18) reduces bias from competing risks. 
Additionally, calendar period adjustment for early vs. late HAART era in our study adjusts 
for competing risks due to immunodeficiency and AIDS-related deaths, which were more 
prevalent in the early HAART era. The higher incidence of prostate cancer among HIV-
infected populations in the HAART compared to pre-HAART era is also consistent with this 
scenario (32). These observations suggest that differences in screening rates, ascertainment, 
and/or survivorship bias, which may be largely attributable to the success of widespread 
HAART use, probably explain discordant results for prostate cancer risk between studies of 
HIV-infected populations.
HIV-related factors showed no significant difference among subjects with vs. without 
prostate cancer diagnosis in our study cohort, except CD4:CD8 ratio, which was higher 
among cases relative to non-cases within the cohort. However, the slightly higher CD4:CD8 
ratio among outcome compared to non-outcome HIV-infected subjects age 40–70 was 
influenced by the lower proportion of outcome subjects with AIDS (5, 9, 12, 30). Protease 
inhibitors were used by the majority of HIV-infected subjects in our cohort. However, in 
contrast to reports suggesting that protease inhibitors may be associated with lower risk of 
prostate cancer (9, 33), we found no significant difference in protease inhibitor use by 
prostate cancer diagnosis.
We examined other risk factors, including family history of prostate cancer, exogenous 
androgen supplement exposure, and high BMI, for possible associations with young-onset 
prostate cancer (9, 10). A positive family history of prostate cancer was more common 
among all subjects with young-onset prostate cancer compared to controls of similar age 
(18.8% vs. 12.3%), consistent with previous studies (8). Androgen supplement use and 
proportions of subjects with BMI >30 kg/m2 were similar between men age 40–55 by 
young-onset prostate cancer diagnosis, while a non-significant increase was observed in the 
proportion of heavy smokers (31.2% vs. 20%). Thus, the only risk factors showing positive 
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associations with young-onset prostate cancer risk in our study were African American race, 
and positive family history.
Considering the elevated risk of prostate cancer among African Americans in the study 
cohort, we also examined cohort characteristics by race. Several prostate cancer risk factors, 
such as BMI, age, smoking, and androgen supplementation (34–36), differed between 
groups by HIV status and race. A positive family history of prostate cancer was reported by 
a higher proportion of African Americans with young-onset prostate cancer compared to all 
African Americans in the study cohort (28.6% vs. 12.0%). More African Americans were 
HIV- or HCV-infected, while fewer reported taking androgen supplements or heavy 
smoking. In contrast to a retrospective study on prostate cancer in an urban cohort of 
predominantly African American HIV-infected subjects with prevalent IDU (5), African 
Americans in our study cohort had a low prevalence of IDU (7.4%), lower rates of HCV 
infection (25.6%), and lower prevalence of heavy smoking (13.7%) than reported in a cross-
sectional study examining the association of heavy smoking and prostate cancer (36). Given 
the nested study design, longitudinal cohort with data collected biannually, and fewer 
confounding factors compared to many prior studies, findings in our study are less likely to 
be confounded by sociodemographic differences, ascertainment bias, and competing risks. A 
notable finding among African Americans in our study was the difference in age of young-
onset prostate cancer diagnoses by HIV-infection status: age 50–54 years in HIV-negative 
subjects vs. 41–50 years in HIV-positive subjects (p=0.11). Although this difference in age 
at diagnosis was not statistically significant, several other studies also noted a trend toward 
younger age at prostate cancer diagnosis in HIV-infected compared to uninfected African 
American men (5, 19–21). Further studies are warranted to evaluate whether HIV-infection 
status is associated with a younger age at prostate cancer diagnosis among men ages 40–55.
Given that African American men are disproportionately represented in HIV-infected 
populations, including our cohort, it is often difficult to disentangle the influence of racial 
composition on prostate cancer burden in HIV-infected populations. Other factors such as 
lower PSA screening rates in African American men (26), potentially resulting from 
competing risks related to comorbidities and mortality, or limited access to care, may 
contribute to decreased estimates of prostate cancer burden among African Americans in 
HIV-infected populations. Among studies reporting a deficit of prostate cancer risk in 
PLWHA (9, 13, 14), the proportion of African Americans ranged from 16 to 40%; these 
proportions overlap with those reported in studies that found a null association between 
HIV-infection and prostate cancer risk, such as (15, 30) and the present study. Due to 
uncertainty regarding the percentage of African Americans with follow-up past age 40 and 
length of follow-up in these other studies, some comprised of mixed gender and sexual 
orientation, the influence of racial composition on prostate cancer risk in these HIV-infected 
populations remains inconclusive. In our analyses of men ages 40–70, models stratified by 
HIV status aimed to examine differences in the association of race with prostate cancer risk 
between groups, but were underpowered in the HIV-uninfected group due to the lower 
proportion of African Americans (17.8%). Consistent with findings from an earlier report 
(17), the stronger racial disparity with respect to prostate cancer risk within the HIV-infected 
group may in part reflect earlier screening in younger African American subjects, allowing 
sufficient statistical power to detect a difference by race in the HIV-infected group. Whether 
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the association of race with prostate cancer risk is stronger in HIV-infected vs. uninfected 
populations remains unclear in our study, and warrants further study in larger cohorts.
A limitation of this study is that our findings are based on a cohort of MSM, and thus may 
not be generalizable to other HIV-infected populations for several reasons. For example, 
sociodemographic characteristics of the MACS are not representative of many lower income 
and less educated HIV-infected populations, which often correlate with reduced healthcare 
access and engagement. Conversely, overdiagnosis of prostate cancer is more likely to result 
from increased engagement with healthcare, particularly among men dealing with the burden 
of HIV-infection and associated comorbidities. However, as reported by Seaberg et al. (30), 
SIRs for prostate cancer in the MACS are below 1 for both HIV-infected and uninfected 
groups, arguing against overdiagnosis in our cohort. SIRs below 1 are also consistent with 
possible underascertainment of prostate cancer, which might stem from stigma associated 
with a prostate cancer diagnosis and consequences of treatment in MSM as discussed by 
Rosser et al. (28). Factors explored in other studies include compromised sexual function 
following treatment in MSM (37, 38) and poorer health outcomes potentially caused by the 
heteronormative slant of prostate cancer treatment options (39, 40). Nonetheless, other 
factors may heighten prostate cancer risk among MSM, particularly androgen use (35), 
which was higher among young gay and bisexual adolescents in comparison to heterosexual 
adolescents in a US study published in 2014 (39). While we found no significant enrichment 
of androgen supplement use in prostate cancer cases overall (10.6 % in cases vs. 14.1% in 
non-cases), or in subjects with young-onset prostate cancer (12.5% in cases vs.12.4% in 
non-cases), the higher prevalence of androgen supplement use among MSM is a 
distinguishing factor compared to many non-MSM populations. Other limitations of the 
study are similar to those of other cohort studies of this scale (30) in that statistical power 
was limited by the number of outcomes. Incident prostate cancer cases in the study, however, 
were comparable to those reported by other studies with a similar focus (5, 18, 19, 30). 
Gleason scores, PSA tests, digital rectal exams, and tumor stage were not available for the 
study cohort, and therefore analyses could not be stratified by these characteristics. Despite 
these limitations, through a nested study design and age-stratified analyses, we identified 
HIV-infected African American men ages 40–55 as an unrecognized subgroup among the 
growing HIV-infected population with elevated risk of prostate cancer (11).
Prostate cancer diagnosis and management are becoming increasingly important issues for 
aging populations with HIV infection (27). Overdiagnosis, overtreatment, and compromised 
quality of life are potential disadvantages of population-wide PSA screenings (24). In 
addition to cost, an important problem with wide-scale PSA screening is the difficulty in 
distinguishing between prostate cancers that are likely to become symptomatic versus those 
that do not. Accordingly, the risk/benefit ratio of PSA screening must be carefully 
considered (24) and informed decisions about screening should follow discussions with 
health care providers about uncertainties, risks, and benefits of screening. Our evaluation of 
prostate cancer risk in an HIV-infected and uninfected cohort suggest that ACS guidelines 
for the general population apply similarly to HIV-infected men with at least ten years life 
expectancy. Consistent with findings by Carter et al.(41), our study demonstrates the 
prognostic significance of positive family history of prostate cancer; it was the only risk 
factor we found to be associated with a young-onset prostate cancer diagnosis (41). This 
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finding in conjunction with other diagnostic parameters may help young HIV-infected and 
uninfected African Americans age 40–55 reach a balanced decision between screening and 
watchful waiting to avoid instances of overdiagnosis and overtreatment without 
compromising overall health outcomes.
In conclusion, we evaluated prostate cancer risk in a prospective cohort of HIV-infected and 
-uninfected MSM and found more than 3-fold increased risk of young-onset prostate cancer 
among African American compared to non-African American men. In view of the racial 
differences in young-onset prostate cancer risk detected in our study, we propose that HIV-
infected African American men be informed of their prostate cancer risk and participate in 
making informed decisions about screening starting at age 45 for those with at least ten 
years life expectancy.
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Table 2
Crude incidence rates of prostate cancer by HIV status and race
Univariate Model Incident Cancers (No.) Person-Years IR (95% CI)
All 47 27800 169.1 (124.2–224.8)
 HIV-uninfected 28 15150 184.8 (122.8–267.1)
 HIV-infected 19 12651 150.2 (90.4–234.5)
Race
 Non-African American 34 22937 148.2 (102.7–207.1)
 African American 13 4863 267.3 (142.3–457.1)
HIV-negative
 Non-African American 23 13180 174.5 (110.6–2618)
 African American 5 1970 253.8 (82.4–592.3)
HIV-positive
 Non-African American 11 9757 112.7 (56.3–201.7)
 African American 8 2893 276.5 (119.4–544.9)
Age 40–55a
 Non-African American 9 14850 60.6 (27.7–115.0)
 African American 7 3494 200.3 (80.5–412.8)
IR, incidence rate per 100,000 person-years
a
Calculated for subjects with follow-up within the specified age range
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